Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S. Cecere SC, et al. Among authors: mazzoni e. Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4. Gynecol Oncol. 2020. PMID: 31699415 Free article.
Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A, Caliolo C, Sponziello F, Nacci A, Quaranta A, Mazzoni E, Lutrino SE, Rizzo P, Calvani N, Orlando L, Schiavone P, Fedele P, D'Amico M, Chetrì MC, Cinefra M, Ferrara P, Cinieri S. Marino A, et al. Among authors: mazzoni e. Tumori. 2015 Sep-Oct;101(5):524-8. doi: 10.5301/tj.5000356. Epub 2015 May 25. Tumori. 2015. PMID: 26045117
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
BMI variation increases recurrence risk in women with early-stage breast cancer.
Fedele P, Orlando L, Schiavone P, Quaranta A, Lapolla AM, De Pasquale M, Ardizzone A, Bria E, Sperduti I, Calvani N, Marino A, Caliolo C, Mazzoni E, Cinieri S. Fedele P, et al. Among authors: mazzoni e. Future Oncol. 2014 Dec;10(15):2459-68. doi: 10.2217/fon.14.180. Future Oncol. 2014. PMID: 25525854
Molecularly targeted endocrine therapies for breast cancer.
Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P, Marino A, D'Amico M, Sponziello F, Mazzoni E, Cinefra M, Fazio N, Maiello E, Silvestris N, Colucci G, Cinieri S. Orlando L, et al. Among authors: mazzoni e. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S67-71. doi: 10.1016/S0305-7372(10)70023-2. Cancer Treat Rev. 2010. PMID: 21129614 Review.
Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, D'Amico M, Mazzoni E, Marino A, Sponziello F, Morelli F, Lombardi L, Silvestris N, Cinieri S. Orlando L, et al. Among authors: mazzoni e. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S83-9. doi: 10.1517/14728222.2011.648925. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443171 Review.
241 results